Anti-fibrotic Treatment for Pulmonary Fibrosis Induced by COVID-19: A Case Presentation

Coronavirus disease 19 infection clinical presentation varies from asymptomatic cases to acute respiratory distress syndromes. In some cases, pulmonary fibrosis is observed after or during the disease. Pirfenidone is an agent approved for the treatment of idiopathic pulmonary fibrosis. Here we repor...

Descripción completa

Detalles Bibliográficos
Autores principales: Sakızcı Uyar, Bahar, Ensarioğlu, Kerem, Kurt, E. Bahar, Özkan, Derya, Özbal Güneş, Serra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Turkish Society of Anaesthesiology and Reanimation 2022
Materias:
Case Report Intensive Care
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9361135/
https://www.ncbi.nlm.nih.gov/pubmed/35801331
http://dx.doi.org/10.5152/TJAR.2021.20450
_version_ 1784764467553239040
author Sakızcı Uyar, Bahar
Ensarioğlu, Kerem
Kurt, E. Bahar
Özkan, Derya
Özbal Güneş, Serra
author_facet Sakızcı Uyar, Bahar
Ensarioğlu, Kerem
Kurt, E. Bahar
Özkan, Derya
Özbal Güneş, Serra
author_sort Sakızcı Uyar, Bahar
collection PubMed
description Coronavirus disease 19 infection clinical presentation varies from asymptomatic cases to acute respiratory distress syndromes. In some cases, pulmonary fibrosis is observed after or during the disease. Pirfenidone is an agent approved for the treatment of idiopathic pulmonary fibrosis. Here we report a patient treated with pirfenidone for pulmonary fibrosis related to coronavirus disease 19.
format Online
Article
Text
id pubmed-9361135
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Turkish Society of Anaesthesiology and Reanimation
record_format MEDLINE/PubMed
spelling pubmed-93611352022-08-18 Anti-fibrotic Treatment for Pulmonary Fibrosis Induced by COVID-19: A Case Presentation Sakızcı Uyar, Bahar Ensarioğlu, Kerem Kurt, E. Bahar Özkan, Derya Özbal Güneş, Serra Turk J Anaesthesiol Reanim Case Report Intensive Care Coronavirus disease 19 infection clinical presentation varies from asymptomatic cases to acute respiratory distress syndromes. In some cases, pulmonary fibrosis is observed after or during the disease. Pirfenidone is an agent approved for the treatment of idiopathic pulmonary fibrosis. Here we report a patient treated with pirfenidone for pulmonary fibrosis related to coronavirus disease 19. Turkish Society of Anaesthesiology and Reanimation 2022-06-01 /pmc/articles/PMC9361135/ /pubmed/35801331 http://dx.doi.org/10.5152/TJAR.2021.20450 Text en © Copyright 2022 authors https://creativecommons.org/licenses/by/4.0/ Content of this journal is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. (https://creativecommons.org/licenses/by/4.0/)
spellingShingle Case Report Intensive Care
Sakızcı Uyar, Bahar
Ensarioğlu, Kerem
Kurt, E. Bahar
Özkan, Derya
Özbal Güneş, Serra
Anti-fibrotic Treatment for Pulmonary Fibrosis Induced by COVID-19: A Case Presentation
title Anti-fibrotic Treatment for Pulmonary Fibrosis Induced by COVID-19: A Case Presentation
title_full Anti-fibrotic Treatment for Pulmonary Fibrosis Induced by COVID-19: A Case Presentation
title_fullStr Anti-fibrotic Treatment for Pulmonary Fibrosis Induced by COVID-19: A Case Presentation
title_full_unstemmed Anti-fibrotic Treatment for Pulmonary Fibrosis Induced by COVID-19: A Case Presentation
title_short Anti-fibrotic Treatment for Pulmonary Fibrosis Induced by COVID-19: A Case Presentation
title_sort anti-fibrotic treatment for pulmonary fibrosis induced by covid-19: a case presentation
topic Case Report Intensive Care
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9361135/
https://www.ncbi.nlm.nih.gov/pubmed/35801331
http://dx.doi.org/10.5152/TJAR.2021.20450
work_keys_str_mv AT sakızcıuyarbahar antifibrotictreatmentforpulmonaryfibrosisinducedbycovid19acasepresentation
AT ensarioglukerem antifibrotictreatmentforpulmonaryfibrosisinducedbycovid19acasepresentation
AT kurtebahar antifibrotictreatmentforpulmonaryfibrosisinducedbycovid19acasepresentation
AT ozkanderya antifibrotictreatmentforpulmonaryfibrosisinducedbycovid19acasepresentation
AT ozbalgunesserra antifibrotictreatmentforpulmonaryfibrosisinducedbycovid19acasepresentation

Ejemplares similares